| abstract |
The present invention relates to novel alpha 1-adrenoceptor antagonists of Formula I: <IMAGE> I in which: p is 0 or 1; t is 0, 1 or 2; X is O, S or NR6 (in which R6 is hydro or (C1-6)alkyl); Y and Z are independently CH or N; R1 is hydro, hydroxy, halo, nitro, amino, cyano, (C1-4)alkylthio, acetylamino, trifluoroacetylamino, methylsulfonylamino, (C1-6)alkyl, (C3-6)cycloalkyl, (C3-6)cycloalkyl (C1-4)alkyl, oxazol-2-yl, aryl, heteroaryl, aryl (C1-4)alkyl, heteroaryl (C1-4)alkyl, (C1-6)alkyloxy, (C3-6)cycloalkyloxy, (C3-6)cycloalkyl (C1-4)alkyloxy, 2-propynyloxy, aryloxy, heteroaryloxy, aryl (C1-4)alkyloxy or heteroaryl (C1-4)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms and aryl or heteroaryl is optionally substituted with one to two substituents independently selected from halo and cyano); R2 is hydro, hydroxy, halo, cyano, (C1-6)alkyl or (C1-6)alkyloxy (wherein alkyl is optionally substituted with one to three halo atoms); R3 is -C (O)R7 (wherein R7 is (C1-6)alkyl, (C3-6)cycloalkyl, di(C1-4)alkylamino, N-(C1-4)alkyl-N-(C1-4)alkyloxyamino, (C1-4)alkyl((C1-4)alkyloxy)amino, pyrrolidin-1-yl, piperidin-1-yl, morpholin-4-yl or piperazin-1-yl); R4 is halo, hydroxy, cyano, (C1-6)alkyl or (C1-6)alkyloxy; and R5 is (C1-6)alkyl; and the pharmaceutically acceptable salts and N-oxides thereof. |